Development of NTS2-selective non-opioid analgesics using artificial intelligence
Frédérique Lussier, Hadrien Mary, Alexandre Murza, Jean-Michel Longpré, Therence Bois, Sébastien Giguère, Pierre-Luc Boudreault, Philippe Sarret · FENS Forum 2024
Chronic pain affects nearly 20% of the Canadian population and is now recognized as a disease by the World Health Organization. Moderate to severe pain is currently treated with opioids which are known to cause various side effects (constipation, nausea, respiratory depression, drowsiness) and strong dependence. A promising alternative is neurotensin, an endogenous neuromodulator peptide which induces analgesia by interacting with its two G-protein coupled receptors NTS1 and NTS2. However, NTS1 activation is also associated with hypotension and hypothermia. Selectivity towards NTS2 is, therefo
ePoster · Neuroscience